AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00414700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChondroCelect implantation
Description: 10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm².
Study NCT02938494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream
Description: Cream
Study NCT02938494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Lotion
Description: Lotion
Study NCT02938494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Cream
Description: Cream
Study NCT00739479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
Study NCT00739479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
Study NCT01451905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
Study NCT01451905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
Study NCT05343949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT exercise program ABC
Description: Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
Study NCT05343949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT exercise program CAB
Description: Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
Study NCT05343949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT exercise program BCA
Description: Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
Study NCT02062606 — intervention group
Intervention type: DEVICE
Intervention: MESA Rail™ Deformity System
Description: MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
Study NCT03521999 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AboutFace
Description: AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
Study NCT03521999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care (eUC)
Description: Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
Study NCT02517710 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stratafix synthetic barbed suture
Description: hysterotomy closure in Cesarian section
Study NCT02517710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stratafix synthetic barbed suture
Description: hysterotomy closure in Cesarian section
Study NCT01374399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise and relaxation
Description: resistance and endurance exercise, 3-5 times per week
Study NCT01374399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise and relaxation
Description: resistance and endurance exercise, 3-5 times per week
Study NCT02415959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon IR
Study NCT04419961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants.
Study NCT00320710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV
Study NCT00320710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to zoledronic acid
Study NCT02169271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT02169271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02169271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00414700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
Study NCT02169271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03038542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-framed text messages
Study NCT03038542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care text messages
Study NCT02229760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir capsules
Study NCT02229760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsules
Study NCT02627664 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: natural history of non dopaminergic signs
Study NCT02594293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN alfa-2a
Description: 180 μg/ 0.5 ml ,hypodermic injection once a week
Study NCT01826331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for Participation
Description: Participants will receive three smoking cessation programs
Study NCT01826331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for Cessation
Description: Participants will have access to a smoking cessation program
Study NCT01694303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study NCT01454323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells
Description: Intracoronary infusion of autologous bone marrow-derived mononuclear cells
Study NCT01694303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study NCT04232423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 Mg ORAL TABLET
Description: * Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4
Study NCT04232423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 Mg ORAL TABLET
Description: * Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4
Study NCT04232423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ORAL TABLET
Description: * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid
Description: The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Similac Liquid Protein Fortifier
Description: For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nestle Microlipid
Description: For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
Study NCT02415959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon® (DR/GR)
Study NCT01677455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Medica Nutrition SolCarb
Description: For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)
Description: The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Liquid Protein Fortifier (Targeted Fortification)
Description: Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
Study NCT04294368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Microlipid (Targeted Fortification)
Description: Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Study NCT00347425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Study NCT04027673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMW ECE Curriculum
Description: The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
Study NCT03143634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Modular Protocol for Mental Health
Description: This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
Study NCT03143634 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment-as-usual
Description: This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
Study NCT02099968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Modification
Description: * Fasting (1st week), followed by:~* Vegetarian and modified DASH diet (plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation, meditation, yoga
Study NCT02099968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Modification / modified DASH
Description: * Modified DASH (vegetarian focused, plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation
Study NCT00200395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
Study NCT02791659 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Automatic beam adjustment function
Description: The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
Study NCT02791659 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Automatic beam adjustment function
Description: The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
Study NCT01881399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence cholangiography (da Vinci surgical system)
Description: Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
Study NCT01881399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual cholangiography
Description: Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
Study NCT01881399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional IOC
Description: Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
Study NCT01953159 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Study NCT01953159 — intervention group
Intervention type: OTHER
Intervention: Patient Questionnaires
Study NCT00077428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00077428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00077428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01410383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken daily
Study NCT01410383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome
Description: Tablets taken daily
Study NCT03534297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapansutrile capsules
Description: Hard opaque capsules containing 100 mg of API.
Study NCT03534297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Hard opaque capsules containing 0 mg of API.
Study NCT01033383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
Study NCT01033383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
Study NCT01033383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Capsule
Description: 36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
Study NCT02139683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: HIFU treatment in patients with fibroadenoma
Study NCT01815021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amorphous calcium carbonate
Study NCT01815021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: crystalline calcium supplements
Study NCT00106028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium (Actonel)
Description: risedronate tablet once a day for one year followed by risedronate once a day for two years
Study NCT00106028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once a day for one year followed by risedronate once a day for two years
Study NCT04479657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QingFei Granule
Description: QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
Study NCT04479657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: 30mg/kg/d,bid, used until to the normalization of blood routine。
Study NCT04479657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Description: 30mg/kg/d,bid, used until to the normalization of blood routine。
Study NCT02739815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline containing a prophylactic Antibiotic 1 g
Description: 500 ml of normal saline containing a prophylactic Antibiotic 1 g.
Study NCT02739815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline containing a prophylactic Antibiotic 1 g
Description: 500 ml of normal saline containing a prophylactic Antibiotic 1 g.
Study NCT02739815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid